J&J breathes some more life into plamotamab and CD28
Two Xencor approaches with questions around them receive the backing of Johnson & Johnson.
Cancer continues to dominate deal making
Since 2016 drug developers have spent $23.6bn in-licensing cancer projects, almost half of the sector’s up-front bill.
Biopharma’s ballooning licensing deal bill
Up-front costs are higher than ever, with preclinical and phase 2 assets showing the most price inflation, according to a new analysis of licensing deal trends.
The search for a better Faslodex continues
Selective oestrogen degraders, or Serds, remain in focus as a key period for reporting clinical data approaches.
